B4GALT1 and cancer: The results demonstrate that the tumor marker of serum IgG glycosylation is galactosylation and its associated glycans and that the B-cell-specific ablation of B4GALT1 reduces HCC formation by reducing serum IgG galactosylation levels and by modulating the associated glycans, meaning that the lower incidence of cancer in women may be related to minor changes in the B-cell B4GALT1 and unchanged serum IgG galactosylation levels.